Senior Scientist (Cell Biology and Technology Unit)

Chugai Pharmabody Research Pte. Ltd. (“CPR”) was established in Singapore as a wholly-owned subsidiary of Chugai Pharmaceutical Co., Ltd (Chugai), a member of Roche group, in January 2012 and started operations on July 2, 2012. Located at Biopolis, (Geneo from September 2026) in Singapore , it aims to generate new antibody drugs based on Chugai’s proprietary antibody engineering technologies, such as recycling antibody®, sweeping antibody®, bispecific antibody, various Fc engineered antibodies,…